Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Research and Innovation Action · Running

Triple-A-COAT Sustainable Development of a Safe and Biobased Antimicrobial, Antifungal and Antiviral Nanocoating Platform

Coordinator
Katholieke Universiteit Leuven, Belgium
Runs
1 September 2022 to 31 August 2026
Status
Running
EU funding
€3.7m
Total cost
€3.7m
Partners
15 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101057992

What the project is doing

In the project's own words, from its summary on CORDIS.

Human pathogens can persist on textiles and high-traffic surfaces for hours, days or even longer when protected in biofilms, increasing risk of infection spreading. Conventional cleaning has no lasting effect as contamination can re-occur almost immediately. Available antimicrobial coatings are based mainly on the release of silver ions and other biocides that present risks for resistance development and environmental damage.

Inorganic nanoparticles are also a concern for human health. Nanocellulose is a versatile nanomaterial obtained from wood pulp or biotechnological methods, which has excellent physical properties for coatings, enabling controllable and standardised application of antimicrobial functionalities. In Triple-A-COAT the 3 forms of nanocellulose will be augmented for antimicrobial/antiviral activity through grafting/adsorption of novel, resistance-proof compounds with excellent activities against bacteria, fungi and/or viruses, and nanopatterning to create bio-inspired antimicrobial surfaces.

Spray coating and thin film applications will be developed, optimising adherence to plastic, metal, textiles and glass. The most effective coatings will be evaluated for antimicrobial/antiviral activity, durability and non-toxicity using ISO standard tests, and in a simulation of a bus environment over 6 months to reach TRL6. A life cycle assessment of the platform will also be completed. The project consortium involves companies, academic and SME partners with leading expertise in novel antimicrobial and antiviral technology, nanocellulose production and functionalisation, coatings development and characterisation, as well as a bus manufacturer and an external User Committee.

Within 5-10 years after the end of the project, the results will be commercialized for impact in the transportation and healthcare sectors, contributing to the better control of infectious disease, and boosting the competitiveness and research leadership of EU industry including SMEs.

Topics

Who is involved

OrganisationCityCountryRole
Katholieke Universiteit LeuvenLeuvenBelgiumCoordinator
Iveco BelgiumDilbeekBelgiumParticipant
Sirris Het Collectief Centrum Van De Technologische IndustrieBruxelles / BrusselBelgiumParticipant
Van Hool N.v.Lier KoningshooiktBelgiumParticipant
SuSoS AGDubendorfSwitzerlandAssociatedpartner
2.-0 Lca Consultants ApsAalborgDenmarkParticipant
CellugySoborgDenmarkParticipant
Melodea LtdRehovotIsraelParticipant
Academisch Ziekenhuis GroningenGroningenNetherlandsParticipant
Sappi Netherlands Services BVMaastrichtNetherlandsParticipant
Educell Podjetje Za Celicno Biologi Jo DooTrzinSloveniaParticipant
Engedi Science LtdBradfordUnited KingdomAssociatedpartner
Imperial College of Science Technology and MedicineLondonUnited KingdomAssociatedpartner
Virology Research Services LimitedSandwichUnited KingdomAssociatedpartner
Stellenbosch UniversityStellenboschSouth AfricaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI